Halberd Corp HALB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HALB is a good fit for your portfolio.
News
-
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
-
Halberd/Athena GTX Research Promises a Much Brighter Future
-
Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill
-
Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.01
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $4.58 Mil
- Volume/Avg
- 2.3 Mil / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,440.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 3
Valuation
Metric
|
HALB
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1,440.00 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
HALB
|
---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.01 |
Interest Coverage | −65.02 |
Quick Ratio
HALB
Profitability
Metric
|
HALB
|
---|---|
Return on Assets (Normalized) | −3,091.66% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
HALB
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Ymhcybdyy | Ckmw | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Gfcvsmwj | Rgyrhn | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Qztrgbgd | Ggstzj | $118.7 Bil | |||
Moderna Inc
MRNA
| Snmnyznt | Vhv | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Kmnqzzxnb | Flqjjgw | $29.7 Bil | |||
argenx SE ADR
ARGX
| Rhskdzmm | Rsdq | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Qwqlvcmr | Npyr | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Qvzvkfz | Vzvgmq | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Xbsmrssm | Vhgzl | $15.0 Bil | |||
Incyte Corp
INCY
| Gxsqhfdc | Vxfrpg | $13.5 Bil |